Cite
MLA Citation
Kaycee Sink et al.. “P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE.” Alzheimer's & dementia, vol. 15, n.d., p. P250. http://access.bl.uk/ark:/81055/vdc_100103407446.0x00001b